German China India

Excellence United

Pharma 4.0: Excellence United Setting New Standards

| Author: Anke Geipel-Kern

“The Cube” Shows Excellence United's Excellence

The atmosphere at the Excellence United Achema trade show booth is bright and optimistic, inspired by the numbers of people streaming to the stand and the success of the joint exhibition. “Discover Digital Excellence” is this year's motto — and many visitors made their way to the exhibition entitled “The Cube”, which formed the centerpoint of the joint trade fair booth. A real eye-catcher in Hall 3, it was simply impossible to miss this exhibit, but inside it concealed an entire smart factory.

A team of designers developed the transparent cube, which was designed to resemble a crystal and represents the group’s excellence. The team at the Cube counter recorded over 400 visitors a day — a figure that speaks for itself.

The project is designed to document the performance capability of the association and, with all due modesty, revolutionize the future of pharmaceutical production.

Olaf J. Müller, CEO Fette Compacting
Olaf J. Müller, CEO Fette Compacting (Bild: Ernst Fesseler, Berlin (ernst.fesseler@web.de))

“With this exhibit we have sent out a clear message to the market,” explains Olaf J. Müller, CEO of LMT Group and Managing Director of Fette Compacting.

On the subject of Pharmaceutical Production 4.0, the corporate alliance has indeed gone on the offensive and taken great strides forward, delivering an IoT platform as the result of a two-year joint development process.

Integration is the Key

On the basis of this platform, users can network machines from the Excellence ­United partners and third-party machines with each other; where it makes sense to do so, the interfaces are standardized in accordance with OPC-UA requirements. “From the initial weighing process to the packaging of drugs in blister packs, we cover the entire process chain, both for batch processes and for continuous processes,” explains Excellence United spokesperson Thomas Hofmaier, Executive Manager Pharmaceuticals at Glatt.

All th

Thomas Hofmaier, Executive Director Pharmaceutical Technology Glatt
Thomas Hofmaier, Executive Director Pharmaceutical Technology Glatt (Bild: Glatt)

e partners’ technologies can be integrated, so OSD lines and manufacturing lines for the production of liquid drugs can be implemented. In the Cube, visitors can see e.g. a continuous tablet production line, with every element from weighing, mixing, granulation, drying, tableting and dedusting to coating with subsequent packaging in blister packs and folded cardboard boxes.

The highlight here: All the lots — from the powder and tablets to the blister packs and outer packaging — are tracked digitally using an approach that is equally well suited to batch production, semi-batch production and fully continuous production. PAT technologies are also implemented in the application.

The active ingredient concentration per tablet is accurately monitored inline. This makes the IoT Hub a central interface via which users can record machine and process parameters and make this data available worldwide — both via the cloud or via internal company networks. Condition monitoring in real-time and predictive maintenance are the next goals.

Competition Stimulates Business

Many companies are currently pursuing the idea of digital integration, particularly software providers and pharmaceutical suppliers. After all, the suffix 4.0 stands for a technology advantage and promises profits — if not immediately, certainly in the future. This means that the competition is not asleep, and there were plenty of interesting new Industry 4.0 approaches on show again at ­Achema, including from Bosch Packaging and IMA.

This makes the question as to what the unique selling points of the EXU IoT Hub are an increasingly pressing one. So where does Excellence United score over its rivals? “Our platform has not been adapted from other industries. Instead, it has been designed from the ground up specifically for pharmaceutical requirements,” emphasizes Müller.

Hofmaier offers up four more arguments into the debate, which he believes are essential for success among pharmaceutical companies: Understanding of customers and applications, experience in the integration of pharmaceutical applications, open technical systems and the ability of the players involved to cooperate. The latter is something that the Alliance has demonstrated yet again with the Cube. A total of around 60 employees were involved right up until the end of the project, each one contributing experience from his company environment and its prior digital background.

Dr. Hagen Gehringer, Executive Director Bausch+Ströbel
Dr. Hagen Gehringer, Executive Director Bausch+Ströbel (Bild: Bausch+Ströbel)

Dr. Hagen Gehringer, Managing Director Technology at Bausch+Ströbel, explained that two sub-projects had been involved in the process: a classic machine building project for the equipment engineering and an IT project that focused on mapping the IoT Hub in the software. Both aspects are closely meshed, since modern high-tech machinery is no longer conceivable without software and sensor systems. In just under nine months, the project team also built a further digital infrastructure from the ground up. Something that you cannot see from the outside of the Cube is that the entire trade fair booth is networked inside it. Each individual stand has Industry 4.0 applications, so the topic is a thread that runs through and ties together all the exhibits.

Siegfried Drost, Executive Director Uhlmann
Siegfried Drost, Executive Director Uhlmann (Bild: Uhlmann)

Siegfried Drost, Sales Director at Uhlmann, explained that the different development teams were constantly pushing each other, comparing them to speedboats whose wakes constantly overlapped.

But What Does Industry Think About Industry 4.0?

It remains to be seen whether pharmaceutical production is ready for the digital change that the Alliance is hoping to set in motion with its new approach. To use the cloud or not? How to handle sensitive data? How do the authorities will act? At the moment, there are any numbers of open questions.

Claußnitzer, Executive Director Harro Höfliger
Claußnitzer, Executive Director Harro Höfliger (Bild: Janine Kyofsky)

“We are currently all on a journey,” says Peter Claußnitzer, CTO of Harro Höfliger. This is a path that machine builders and drug companies need to take together. “We can only offer customers digital solutions if we have corresponding digitalized value creation chains,” emphasizes Claußnitzer. On the other hand, the services currently being planned via the Hub can only be implemented if customers open themselves up and make the necessary data available. One thing is clear — the CEOs are unanimous that the industry is changing. Increasingly, pharmaceutical companies are looking to purchase complete technology solutions rather than individual machines. This means additional tasks and increased responsibility for suppliers. According to Hofmaier, projects are becoming more dynamic and agile, and the specification process is increasingly being left to the machine builder in the production line creation process. And this is exactly where the CEOs see a further strength of the partner companies: Project expertise and trust-based customer relationships create the basis from which joint orders are generated.

Although the pharmaceutical industry is not at the forefront of introducing new technologies, initial indicators show that digitalization is on its way, and the ­Excellence United partners have taken great strides. “When the first company comes with an idea for a 4.0 factory of the future, we will be ready to offer a solution,” emphasizes Hofmaier.

Content of the Article:

Comments are being loaded ....

Leave a comment

The comment is checked by an editor and will be released soon.

  1. Avatar
    Avatar
    Edited by at
    Edited by at
    1. Avatar
      Avatar
      Edited by at
      Edited by at

Comments are being loaded ....

Report comment

Kommentar Freigeben

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

Freigabe entfernen

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

copyright

This article is protected by copyright. You want to use it for your own purpose? Contact us via: support.vogel.de/ (ID: 45483019 / Pharma & Food)